JAMESTOWN
10.11.2020 10:02:17 CET | Business Wire | Press release
Global real estate company Jamestown today announced the acquisition of three historic office buildings in the up-and-coming Mülheim area of Cologne – the city that is home to Jamestown’s European headquarters. The acquisition marks the firm’s first-ever acquisition in Germany, and its second in Europe in less than a year.
Formerly an industrial neighborhood, Mülheim has, over the past decade, become a thriving area of redevelopment that attracts companies seeking creative spaces. Constructed between 1890 and 1914, the buildings at Schanzenstrasse 22, 24, and 28 are home to a mix of multi-media and entertainment companies, including prominent television production company Brainpool TV. The 34,545-square meter buildings are an attractive blend of post-industrial architecture. Jamestown purchased the buildings with two institutional investors from a group of private investors.
“We have been investing in US real estate from Cologne for 37 years. Our first project in Germany is an important milestone for Jamestown. One of our core competencies at Jamestown is the revitalization of old industrial buildings and we see great potential for this in Europe as well, ” said Christoph Kahl, Chairman of Jamestown.
Jamestown has a long track record of revitalizing historic, industrial buildings into neighborhood destinations and office hubs specializing in technology and content creation. This development strategy has proven to be an economically, socially, and environmentally responsible alternative to new construction. Jamestown prides itself on preserving cities’ industrial pasts, while bringing new life into local communities. Its leadership team continues to see many opportunities to expand this adaptive reuse strategy across Europe, with its rich industrial heritage and strong urban cultures.
“We are excited to add Schanzenstrasse to our growing European footprint. Technology, media, and content firms are resilient, durable sectors that are thriving in the current market. Our focus is on mixed-use projects that create ecosystems where businesses can connect to one another and the consumer. Mülheim, and our other neighbors, are part of that ecosystem,” said Michael Phillips, President of Jamestown.
Jamestown worked with DLA Piper and the seller with McDermott, Will & Emery for legal counsel. The seller was represented by Tresono Family Office. The property will be managed by Apleona Real Estate GmbH.
Since it was established in 1983, Jamestown has been a recognizable name in Germany for operating real estate funds and as a leading landlord and property manager of mixed-use projects in the U.S. that offer commercial office, residential, and retail spaces.
Jamestown made its first European acquisition in December 2019, when it bought the historic Groot Handelsgebouw in Rotterdam, the Netherlands. The company’s roughly $12 billion / EUR 10 billion portfolio includes some of the most iconic buildings and landmarks in the U.S. including One Times Square in New York, Ghirardelli Square in San Francisco, and Ponce City Market in Atlanta.
###
About Jamestown
Jamestown was established in 1983 as an investment and management company focused on income-producing real estate in the United States. Since then, Jamestown has grown its portfolio of assets in key markets throughout the U.S. and expanded its investment footprint to South America and Europe. Jamestown's capabilities include acquisitions, capital markets, property management, asset management, retail leasing, design, sustainability, and risk management. Jamestown has headquarters in Cologne, Germany and Atlanta, Georgia and offices in Amsterdam, New York, Boston, San Francisco, Los Angeles, and Bogota, Colombia. For more information, visit www.jamestownlp.com
.
Photos:
https://jamestown.canto.com/b/G7E1O
View source version on businesswire.com: https://www.businesswire.com/news/home/20201110005543/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Barilla Opens Global Call for Startups Through Good Food Makers 202625.5.2026 11:47:00 CEST | Press release
The program has involved over 1,100 startups across 50+ countries, delivering 26 pilot projects. Barilla Group has opened applications for the 2026 edition of Good Food Makers, its global open innovation program designed to co-develop and test new innovative solutions with startups and innovators inside real industrial environments. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260521973445/en/ Since its launch in 2019, the program has involved more than 1,100 startups from over 50 countries, leading to 26 pilot projects, with over 20 projects currently active thanks to the solutions developed by the program’s alumni. This highlights the program’s role as a concrete platform for industrial scalable innovation. The 2026 edition comes at a pivotal moment for the company, following the launch of BITE (Barilla Innovation & Technology Experience), the new innovation center dedicated to developing the next generation of food prod
JEOL: Sales Launch of the Laser SEM System “LazEdge”25.5.2026 10:16:00 CEST | Press release
JEOL Ltd. (President & CEO: Izumi Oi) has developed the “LazEdge”, an SEM system equipped with a laser processing system, and begins sales on May 25, 2026. Cross-section preparation instruments such as the focused ion beam system (FIB system), are widely used in science and technology fields across research institutes, universities, and industries. In recent years, demand is increasing for a system that can process large-areas at a high speed, while achieving high-quality of the processed surface. “LazEdge” is an instrument integrating JEOL’s SEM with the laser technology proprietary of Hamamatsu Photonics K.K., and enables laser processing inside the specimen chamber of the electron microscope. This system enables high-quality cross-section specimens produced through high-speed, large-area processing to be transferred seamlessly to subsequent analyses, such as SEM observation, elemental analysis, and crystal orientation analysis, without exposure to the external environment. As a resu
TFG-001, A Novel 3D Neural Microtissue Cell Therapy, Demonstrates Superior Functionality and Reinnervation for Parkinson’s Disease25.5.2026 08:00:00 CEST | Press release
TreeFrog Therapeutics, a regenerative medicine biotech company developing next-generation cell therapies, today announced that it will present new preclinical data on TFG-001 at the 7th World Parkinson’s Conference. TFG-001, a 3D neural microtissue cell therapy, demonstrated rapid dopamine release and extensive graft-derived reinnervation across multiple advanced translational Parkinson’s disease models—supporting its potential as a best-in-class candidate. The critical need for reinnervation in Parkinson's disease In Parkinson's disease, an estimated 60–80% of dopaminergic neurons are already lost before motor symptoms even appear. The nigrostriatal pathway degenerates, destroying the essential wiring that connects dopamine-producing neurons to movement control. While chemical dopamine replacements (like levodopa) can manage symptoms, they cannot restore the spatial precision, feedback loops, or dynamic regulation of a healthy brain network. To achieve true functional restoration, it
Galderma Receives U.S. FDA Approval for Differin® Epiduo® Acne Gel Prescription-to-OTC Switch22.5.2026 18:25:00 CEST | Press release
A unique Prescription-to-OTC switch in acne care, this approval expands access to a dermatologist-trusted, prescription-strength treatment for millions of acne sufferers ages 12 years and older Backed by more than 15 years of real-world dermatologist use and a robust clinical research program, this milestone demonstrates the depth of science behind the Differin® and Epiduo® heritage Adapalene plus benzoyl peroxide (0.1/2.5%) was the first FDA-approved, stable, fixed- dose prescription acne treatment to combine of benzoyl peroxide with a retinoid, and is now available over-the-counter The formulation is engineered to target multiple causes of acne more effectively than either of its individual active ingredients alone Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) us
Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press release
Avanzanite will commercialise and distribute PYRUKYND in Europe under its exclusive agreement with Agios Avanzanite is committed to collaborating with local authorities in the EU to enable access to PYRUKYND for adult patients with thalassaemia Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full releas
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom